Results of entecavir treatment of chronic hepatitis B Magdalena Rogalska-Płońska, Tadeusz Wojciech Łapiński Medical Science Review - Hepatologia 2011; 11 44-46 aaICID: 970917
Article type: Review article
IC™ Value: 3.40
Abstract provided by Publisher
Hepatitis B virus is a main cause of chronic hepatitis regarding 350 million people
worldwide, leading to life-threatening conditions: liver cirrhosis and hepatocellular carcinoma.
The worsening progress may be blocked or delayed by the effective therapy. Entecavir
is an oral nucleoside analogue, safe and well tolerated, very effective inhibitor of HBV polymerase
resulting in rapid viral suppression, histological improvement and ALT normalization.
In several randomized, multicentre trials entecavir was effective in nucleoside-naïve and lamivudine-
refractory patients, hepatitis B e antigen positive or negative as well as patients with
decompensated liver cirrhosis.